Ulcerative colitis: Current and future treatment strategies

Digestive Diseases

Volumn 31, Issue 1, 2013, Pages 91-94

  Lissner, Donata ^a   Siegmund, Britta ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cyclosporine; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CD8 ANTIGEN; CTLA 4IG; CYCLOSPORIN; INFLIXIMAB; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 9; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; PREDNISOLONE; TOFACITINIB; TRANSCRIPTOME; UNCLASSIFIED DRUG; CALCINEURIN INHIBITOR;

ARTICLE; BIOLOGICAL THERAPY; CD8+ T LYMPHOCYTE; COLON RESECTION; DISEASE COURSE; DISEASE SEVERITY; DRUG HALF LIFE; DRUG MEGADOSE; ELECTIVE SURGERY; FOLLOW UP; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LONG TERM CARE; LOW RISK POPULATION; PANCOLITIS; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; REMISSION; STEROID THERAPY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT FAILURE; TREATMENT RESPONSE; ULCERATIVE COLITIS; CONFERENCE PAPER; DRUG EFFICACY; DRUG TREATMENT FAILURE; NATURAL KILLER CELL; PHARMACEUTICAL CARE; TH2 CELL;

COLITIS, ULCERATIVE; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84879595723     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000347194     Document Type: Article

References (17)

1. Dignass A, Preiss JC, Aust DE, Autschbach F, Ballauff A, Barretton G, Bokemeyer B, Fichtner-Feigl S, Hagel S, Herrlinger KR, Jantschek G, Kroesen A, Kruis W, Kucharzik T, Langhorst J, Reinshagen M, Rogler G, Schleiermacher D, Schmidt C, Schreiber S, Schulze H, Stange E, Zeitz M, Hoffmann JC, Stallmach A: Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011 (in German). Z Gastroenterol 2011; 49: 1276-1341.
2. Kruis W, Kiudelis G, Racz I, Gorelov IA, Pokrotnieks J, Horynski M, Batovsky M, Kykal J, Boehm S, Greinwald R, Mueller R: Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58: 233-240.
3. Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Borner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H: Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 762-769.
4. Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, Arts J, D'Hoore A, Penninckx F, Rutgeerts P: Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-1031. (Pubitemid 37193449)
5. Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, Rutgeerts P: Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4: 760-765. (Pubitemid 43833506)
6. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476. (Pubitemid 41770166)
7. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-787.
8. Panaccione R, Ghosh S, Middleton S, Velazquez JRM, Khalif I, Flint HJ, Hoogstraten HJ, Zheng H, Danese S, Rutgeerts P: Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial. J Crohns Colitis 2011; 5(suppl):S68-S68.
9. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A, Curman B: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-1811. (Pubitemid 40824691)
10. Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Nachury M, Savoye G, Moreau J, Delchier J, Ricart E, Cosnes J, Lopez-Sanroman A, Dewit O, Carbonnel F, Bommelaer G, Coffin B, Van Assche G, Esteve M, Faarkila M, Perez A, Mary J, Colombel J, Lemann M: Ciclosporin versus infliximab in acute severe ulcerative colitis refractory to intravenous steroids: a randomized study (abstract). Gastroenterology 2011; 140: 619.
11. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR: Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
12. Mayer L, Kaser A, Blumberg RS: Dead on arrival: understanding the failure of CTLA4-immunoglobulin therapy in inflammatory bowel disease. Gastroenterology 2012; 143: 13-17.
13. Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB: Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology 2012; 143: 62-69.e4.
14. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, Saabye MJ, Barks JL, Kishore N, Morris DL: Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010; 7: 41.
15. Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W: Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367: 616-624.
16. McKinney EF, Lyons PA, Carr EJ, Hollis JL, Jayne DR, Willcocks LC, Koukoulaki M, Brazma A, Jovanovic V, Kemeny DM, Pollard AJ, Macary PA, Chaudhry AN, Smith KG: A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 2010; 16: 586-591.
17. Lee JC, Lyons PA, McKinney EF, Sowerby JM, Carr EJ, Bredin F, Rickman HM, Ratlamwala H, Hatton A, Rayner TF, Parkes M, Smith KG: Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011; 121: 4170-4179.